99% for the Coolibar umbrella alone, higher than 90% for black, and lower than 90% for the various nonblack colors.
Oral Minocycline in Treatment of Cutaneous Sarcoidosis

C
urrently, therapeutic techniques used to treat cutaneous sarcoidosis rely on limited data from evidenced-based research. 1,2 Bachelez et al 3 conducted a prospective study in which 10 of 12 patients showed improvement after minocycline therapy, and Antonovich and Callen 4 reported the case of 1 woman who was successfully treated with doxycycline. On the basis of these encouraging reports, our clinic began to use minocycline, a commonly used anti-inflammatory acne therapy that does not require laboratory monitoring, as a first-line treatment for cutaneous sarcoidosis. The present retrospective study sought to evaluate our experience with minocycline treatment and to compare its effectiveness across sex and race.
Methods. This retrospective study was approved by our institutional review board. The primary data sources were paper and electronic medical records of patients with cutaneous sarcoidosis treated with minocycline at the Uni- Umbrella 6 (Coolibar sun umbrella) blocked the most UVR, and umbrella 13 (white Totes) blocked the least UVR. Umbrellas 1, 3, 8, 9, 10, 11, 12, 14, 15, 16, 18, 19, 22, and 23 were categorized as black. Box plots along the axes correspond to the measurements on the axes. Information in the x-axis box plot represents more Farther data. The outlier (small circle) under the x-axis corresponds to measurement 13. The y-axis box plot represents more Closer data. Three outliers (small circles) parallel to the y-axis correspond to measurements 4, 5, and 13. Box plot lines correspond to 25%, 50%, and 75%, and whiskers stretch from 25% and 75%. When outliers are farther than 1.5 times interquartile range, the outlier is represented with a dot. One outlier appears below the Farther axis, umbrella 13, which means that umbrella 13 stands apart for Farther; 3 outliers are charted along the Closer axis.
tient's age, race, sex, extent of skin disease, systemic involvement, prior therapies, duration of minocycline use, and the outcome of this therapy. The outcomes were categorized into 3 groups based on the percentage of body surface area (BSA) that showed remission of lesions: complete remission indicated resolution across 100% of the affected BSA; partial remission indicated 50% BSA resolution; and no remission indicated 0% BSA resolution.
Patients met inclusion criteria if they sought treatment for disfiguring, biopsy-proven cutaneous sarcoidosis lesions that were extensive enough to require oral therapy. The outcome of oral therapy was recorded after at least 2 months of use, unless adverse events caused premature discontinuation. In addition, these patients were required to undergo and adhere to the regimen of minocycline treatment as prescribed by a UPMC dermatologist (J.C.E.).
Statistical analysis (significance, PϽ.05) included the 1-proportion z test to evaluate difference in response to therapy across ages, the Mann-Whitney U test with a null probability of 50% to determine if more patients responded to therapy than not, and the Fisher exact test to determine all other differences, such as differences in response across race and sex.
Results. Twenty-seven patients met the inclusion criteria. Twenty-five had moderately extensive lesions (maculopapular, nodular, or plaque lesions on the face, torso, and/or extremities), and 2 had severe ulcerative lesions (scalp); no patients had classic lupus pernio (infiltrative and/or indurated plaquelike lesions). The average age of the patients at time of diagnosis of cutaneous sarcoidosis was 43 years. There were 14 men and 13 women; 17 were black, and 10 were white. Seven patients experienced lesions on the skin only; 17 had pulmonary and skin involvement; and 1 had ocular, pulmonary, and skin involvement. Sinus, muscle, and parotid involvement occurred with skin disease individually once as well. At the time of presentation, 2 patients were undergoing steroid treatment for pulmonary sarcoidosis and had persistent cutaneous lesions prior to minocycline therapy, and they continued prednisone treatment to preserve lung function. Minocycline was prescribed as first-line treatment in 18 patients and as second-line treatment in the remaining 9 (for 8 of these 9 patients, hydroxychloroquine treatment had failed, and prednisone had failed for 1 with skin-only disease). Owing to the extent of granuloma load in the skin, topical and intralesional steroids were not used during oral treatment. The average length of time until the initial therapy was assessed was 4.1 months.
Of 27 patients, 6 (22%) had complete remission; 14 (52%) had partial remission; and 7 (26%) had no remission. Of the 2 severe ulcerative cases, 1 achieved a partial remission and 1 no remission. In total, 20 of 27 (74%) patients showed response to the treatment, and the proportion of those who responded was significantly greater than those who did not respond (P=.02) (Figures 1 and  Figure 2 ). There was no difference in the response of minocycline across age, race, or sex.
Adverse events often included dizziness, nausea, and blue skin hyperpigmentation. Six patients experienced hyperpigmentation, limited in 4 of these cases to the site of the lesion. White patients were significantly more likely to experience an adverse event than black patients (P =.04), but there was no significant difference across sex.
Discussion. As a whole, this study is limited by its retrospective nature, but it appears that minocycline therapy is a promising option for treating moderate cutaneous sarcoidosis. In total, 20 of 27 patients responded to therapy (74%), and significantly more patients responded than those who did not respond. After reviewing the current literature, our clinic chooses to treat cutaneous sarcoidosis using a monotherapeutic ladder in which minocycline is prescribed as first-line therapy, followed by hydroxychloroquine, methotrexate, thalidomide, and biological agents. Randomized controlled trials are needed to further establish and compare the effectiveness of minocycline as well as all other treatments. Talora Steen, BS Joseph C. English III, MD
